FDA Adverse Event Malfunction Summary report: N

RESOLUTE INTEGRITY RX

MDR report key: 8225796 · Received January 8, 2019

Report

Report Number
9612164-2019-00096
Event Type
Malfunction
Date Received
January 8, 2019
Date of Event
August 30, 2018
Report Date
January 8, 2019
Manufacturer
MEDTRONIC IRELAND
Product Code
NIQ
PMA / PMN Number
P110013
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

A2=AVERAGE AGE A3= MAJORITY GENDER B3=DATE OF PUBLICATION OPTICAL COHERENCE TOMOGRAPHY PREDICTORS FOR RECURRENT RESTENOSIS AFTER PACLITAXEL-COATED BALLOON ANGIOPLASTY FOR DRUG-ELUTING STENT RESTENOSIS. DOI: 10.1253/CIRCJ.CJ-18-0464. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

548 DRUG-ELUTING STENT (DES) IN-STENT RESTENOSIS (ISR) LESIONS WERE EXCLUSIVELY TREATED WITH PCB ANGIOPLASTY FOR THE FIRST TIME BETWEEN (B)(6)2008 AND (B)(6) 2016. MEDTRONIC ZOTAROLIMUS AND RESOLUTE ZOTAROLIMUS-ELUTING STENTS WERE AMONG THE DES THAT EXHIBITED RESTENOSIS. LESIONS TREATED INCLUDED THE LEFT MAIN, LAD, LEFT CIRCUMFLEX AND RIGHT. THIS STUDY INVESTIGATED THE ASSOCIATION BETWEEN OCT FINDINGS AND MID-TERM ANGIOGRAPHIC OUTCOMES. THE MAIN FINDINGS OF THE STUDY WERE: (1) THE HETEROGENEOUS PATTERN WAS ASSOCIATED WITH RECURRENT RESTENOSIS AT FOLLOW-UP; (2) SMALLER POST-PROCEDURAL MLA, CAUSED PRIMARILY BY PERSISTENT STENT UNDEREXPANSION, WAS ALSO A MAIN CAUSE OF RECURRENT RESTENOSIS; AND (3) PREVIOUS STENT FRACTURE, HETEROGENEOUS PATTERN, AND STENT UNDEREXPANSION WERE INDEPENDENT RISK FACTORS FOR RECURRENT RESTENOSIS

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
21921 RESOLUTE INTEGRITY RX STENT, CORONARY, DRUG-ELUTING NIQ MEDTRONIC IRELAND UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 69 YR